# EDGAR Filing Document

**Accession Number:** 0001401914
**File Stem:** 0001493152-26-026666
**Filing Date:** 2026-6
**Character Count:** 4208
**Document Hash:** cf5f94ffad226add8ef1f5a9807c7480
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001493152-26-026666.hdr.sgml**: 20260601

**ACCESSION NUMBER**: 0001493152-26-026666

**CONFORMED SUBMISSION TYPE**: DEFA14A

**PUBLIC DOCUMENT COUNT**: 1

**FILED AS OF DATE**: 20260601

**DATE AS OF CHANGE**: 20260601

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Dare Bioscience, Inc.
- **CENTRAL INDEX KEY:** 0001401914
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 204139823
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** DEFA14A
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-36395
- **FILM NUMBER:** 261052288

**BUSINESS ADDRESS:**
- **STREET 1:** 3655 NOBEL DRIVE
- **STREET 2:** SUITE 260
- **CITY:** SAN DIEGO
- **STATE:** CA
- **ZIP:** 92122
- **BUSINESS PHONE:** 858-926-7655

**MAIL ADDRESS:**
- **STREET 1:** 3655 NOBEL DRIVE
- **STREET 2:** SUITE 260
- **CITY:** SAN DIEGO
- **STATE:** CA
- **ZIP:** 92122

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Cerulean Pharma Inc.
- **DATE OF NAME CHANGE:** 20090714

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Tempo Pharmaceuticals Inc
- **DATE OF NAME CHANGE:** 20070604

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**SCHEDULE 14A**

PROXY STATEMENT PURSUANT TO SECTION 14(A) OF THE

SECURITIES EXCHANGE ACT OF 1934

---

| | | |
|:---|:---|:---|
| Filed by the Registrant ☒ | Filed by the Registrant ☒ | Filed by a Party other than the Registrant ☐ |
| Check the appropriate box: | Check the appropriate box: |  |
| ☐ | Preliminary Proxy Statement |  |
| ☐ | **Confidential, for Use of the Commission only (as permitted by Rule 14a-6(e)(2))** | **Confidential, for Use of the Commission only (as permitted by Rule 14a-6(e)(2))** |
| ☐ | Definitive Proxy Statement |  |
| ☒ | Definitive Additional Materials |  |
| ☐ | Soliciting Material under § 240.14a-12 | Soliciting Material under § 240.14a-12 |

---

**DARÉ BIOSCIENCE, INC.**

(Name of Registrant as Specified In Its Charter)

(Name of Person(s) Filing Proxy Statement if Other Than the Registrant)

Payment of Filing Fee (Check all boxes that apply):

☒ No fee required <br> ☐ Fee paid previously with preliminary materials <br> ☐ Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11

SUPPLEMENT TO PROXY STATEMENT<br> FOR THE ANNUAL MEETING OF STOCKHOLDERS<br> TO BE HELD ON JUNE 11, 2026

This proxy statement supplement (this "Supplement"), dated June 1, 2026, supplements the proxy statement filed by Daré Bioscience, Inc., a Delaware corporation ("Daré," the "Company" and "we," "us" or "our"), with the Securities and Exchange Commission on April 28, 2026 (the "Proxy Statement") relating to the proxies being solicited by Daré's board of directors in connection with Daré's 2026 annual meeting of stockholders to be held on June 11, 2026 (and any adjournment or postponement thereof, the "Annual Meeting"). This Supplement should be read together with the Proxy Statement. Other than as set forth below, no changes have been made to the Proxy Statement.

<u>Engagement of Proxy Solicitor</u>

We engaged Okapi Partners LLC ("Okapi"), an independent proxy solicitation and advisory firm, to provide strategic advice and to assist in soliciting proxies on our behalf in connection with the Annual Meeting. Okapi may solicit proxies in person, by telephone, or by other means of communication, including by other electronic means of communication. We agreed to pay Okapi a fee of $15,000, plus additional fees and expenses, for such services. We have also agreed to indemnify Okapi against certain liabilities relating to or arising out of its engagement.

As stated in the Proxy Statement, we will pay for the entire cost of soliciting proxies. Our directors and employees may solicit proxies in person, by telephone, or by other means of communication. None of our directors or employees will be paid any additional compensation for soliciting proxies. We may also reimburse brokerage firms, banks, dealers and other similar organizations for the cost of forwarding proxy materials to beneficial owners.